Search
Domperidone
go.drugbank.com/drugs/DB01184ApprovedInvestigationalVet approvedA specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
Ajmaline
go.drugbank.com/drugs/DB01426ApprovedWithdrawnIt is a class Ia antiarrhythmic agent that apparently acts by changing the shape and threshold of cardiac action potentials.
Elacestrant
go.drugbank.com/drugs/DB06374ApprovedInvestigational[A256838,L44918] In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Methdilazine
go.drugbank.com/drugs/DB00902ApprovedMethdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus.
Octopamine
go.drugbank.com/drugs/DB13251ExperimentalIt has been used as a nootropic, and therefore it and all of its enantiomer are prohibited by the World Anti-doping Agency (WADA) as of 2014.
Q-Derp1
go.drugbank.com/drugs/DB05857ExperimentalQ-Derp1 is developed by Cytos Biotechnology as an immunodrug. It is an antigen for the prevention of various major chronic diseases. Derp1 is the dominant allergic protein found in dust mite feces.
Stanolone
go.drugbank.com/drugs/DB02901IllicitInvestigationalDihydrotestosterone (DHT) is generated by a 5-alpha reduction of testosterone. Unlike testosterone, DHT cannot be aromatized to estradiol therefore DHT is considered a pure androgenic steroid.
Bambermycins
go.drugbank.com/drugs/DB11377ExperimentalVet approvedThey are used as an additive in food ingested by chickens and swine. The bambermycin complex of antibiotics consists primarily of moenomycins A and C.
RPI-MN
go.drugbank.com/drugs/DB17957Experimental[A260132] Being developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of neurological and immune disorders.[L47107]
Nurulimab
go.drugbank.com/drugs/DB18946InvestigationalNurulimab is under investigation in clinical trial NCT05732805 (A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-pd-1 Compared to Anti-pd-1 Monotherapy as First-line Treatment in